;PMID: 1581879
;source_file_2922.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..47] = [t:0..47]
;1)sentence:[e:53..173] = [t:53..173]
;2)section:[e:177..220] = [t:177..220]
;3)section:[e:224..306] = [t:224..306]
;4)sentence:[e:310..534] = [t:310..534]
;5)sentence:[e:535..696] = [t:535..696]
;6)sentence:[e:697..880] = [t:697..880]
;7)sentence:[e:881..1057] = [t:881..1057]
;8)sentence:[e:1058..1217] = [t:1058..1217]
;9)sentence:[e:1218..1280] = [t:1218..1280]
;10)sentence:[e:1281..1427] = [t:1281..1427]
;11)section:[e:1431..1475] = [t:1431..1475]

;section 0 Span:0..47
;Cancer Genet Cytogenet.  1992 Apr;59(2):128-34.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..12] Genet) (NNP:[13..22] Cytogenet)
        (.:[22..23] .) (CD:[25..29] 1992) (NN:[30..35] Apr;5) (CD:[35..36] 9)
        (NN:[36..37] -LRB-) (NN:[37..38] 2) (-RRB-:[38..39] -RRB-)
        (::[39..40] :) (CD:[40..46] 128-34) (.:[46..47] .)))

;sentence 1 Span:53..173
;Detection of MYCN amplification in three neuroblastoma cell lines by 
;non-radioactive chromosomal in situ hybridization.
;[66..70]:gene-rna:"MYCN"
;[71..84]:variation-type:"amplification"
;[94..107]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (NN:[53..62] Detection))
    (PP (IN:[63..65] of)
      (NP (NN:[66..70] MYCN) (NN:[71..84] amplification)))
    (PP (IN:[85..87] in)
      (NP (CD:[88..93] three) (NN:[94..107] neuroblastoma) (NN:[108..112] cell)
          (NNS:[113..118] lines)))
    (PP (IN:[119..121] by)
      (NP
        (ADJP (AFX:[123..126] non) (HYPH:[126..127] -)
              (JJ:[127..138] radioactive))
        (JJ:[139..150] chromosomal)
        (ADJP (FW:[151..153] in) (FW:[154..158] situ))
        (NN:[159..172] hybridization)))
    (.:[172..173] .)))

;section 2 Span:177..220
;McRobert TL, Rudduck C, Kees UR, Garson OM.
(SEC
  (FRAG (NNP:[177..185] McRobert) (NNP:[186..188] TL) (,:[188..189] ,)
        (NNP:[190..197] Rudduck) (NNP:[198..199] C) (,:[199..200] ,)
        (NNP:[201..205] Kees) (NNP:[206..208] UR) (,:[208..209] ,)
        (NNP:[210..216] Garson) (NNP:[217..219] OM) (.:[219..220] .)))

;section 3 Span:224..306
;Department of Cytogenetics, St. Vincent's Hospital, Fitzroy, Victoria, 
;Australia.
(SEC
  (FRAG (NNP:[224..234] Department) (IN:[235..237] of)
        (NNP:[238..250] Cytogenetics) (,:[250..251] ,) (NNP:[252..255] St.)
        (NNP:[256..263] Vincent) (POS:[263..265] 's) (NNP:[266..274] Hospital)
        (,:[274..275] ,) (NNP:[276..283] Fitzroy) (,:[283..284] ,)
        (NNP:[285..293] Victoria) (,:[293..294] ,) (NNP:[296..305] Australia)
        (.:[305..306] .)))

;sentence 4 Span:310..534
;A non-radioactive chromosomal in situ hybridization technique utilizing a 
;biotin-streptavidin-polyalkaline-phosphatase complex was successfully applied
;to  three neuroblastoma cell lines for detection of MYCN amplification.
;[392..404]:gene-protein:"streptavidin"
;[418..429]:gene-protein:"phosphatase"
;[473..486]:malignancy-type:"neuroblastoma"
;[515..519]:gene-rna:"MYCN"
;[520..533]:variation-type:"amplification"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[310..311] A)
        (ADJP (AFX:[312..315] non) (HYPH:[315..316] -)
              (JJ:[316..327] radioactive))
        (JJ:[328..339] chromosomal)
        (NML
          (ADJP (FW:[340..342] in) (FW:[343..347] situ))
          (NN:[348..361] hybridization))
        (NN:[362..371] technique))
      (VP (VBG:[372..381] utilizing)
        (NP (DT:[382..383] a)
          (NML (NN:[385..391] biotin) (HYPH:[391..392] -)
               (NN:[392..404] streptavidin) (HYPH:[404..405] -)
               (NN:[405..417] polyalkaline) (HYPH:[417..418] -)
               (NN:[418..429] phosphatase))
          (NN:[430..437] complex))))
    (VP (VBD:[438..441] was)
      (ADVP (RB:[442..454] successfully))
      (VP (VBN:[455..462] applied)
        (NP-1 (-NONE-:[462..462] *))
        (PP (TO:[463..465] to)
          (NP (CD:[467..472] three) (NN:[473..486] neuroblastoma)
              (NN:[487..491] cell) (NNS:[492..497] lines)))
        (PP (IN:[498..501] for)
          (NP
            (NP (NN:[502..511] detection))
            (PP (IN:[512..514] of)
              (NP (NN:[515..519] MYCN) (NN:[520..533] amplification)))))))
    (.:[533..534] .)))

;sentence 5 Span:535..696
;These cell  lines, designated PER-106, PER-107, and PER-108, were derived
;from consecutive  bone marrow samples taken from a patient with stage IV
;neuroblastoma.
;[673..681]:malignancy-clinical-stage:"stage IV"
;[682..695]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[535..540] These) (NN:[541..545] cell) (NNS:[547..552] lines))
      (,:[552..553] ,)
      (VP (VBN:[554..564] designated)
        (NP (NN:[565..572] PER-106) (,:[572..573] ,) (NN:[574..581] PER-107)
            (,:[581..582] ,) (CC:[583..586] and) (NN:[587..594] PER-108))))
    (,:[594..595] ,)
    (VP (VBD:[596..600] were)
      (VP (VBN:[601..608] derived)
        (NP-1 (-NONE-:[608..608] *))
        (PP (IN:[609..613] from)
          (NP
            (NP (JJ:[614..625] consecutive)
              (NML (NN:[627..631] bone) (NN:[632..638] marrow))
              (NNS:[639..646] samples))
            (VP (VBN:[647..652] taken)
              (NP (-NONE-:[652..652] *))
              (PP (IN:[653..657] from)
                (NP
                  (NP (DT:[658..659] a) (NN:[660..667] patient))
                  (PP (IN:[668..672] with)
                    (NP
                      (NML (NN:[673..678] stage) (CD:[679..681] IV))
                      (NN:[682..695] neuroblastoma))))))))))
    (.:[695..696] .)))

;sentence 6 Span:697..880
;The cell  line derived at diagnosis (PER-106) exhibited MYCN amplification in
;the form of  variable numbers of double-minute chromosomes, small fragments,
;and rings of  varying sizes.
;[753..757]:gene-rna:"MYCN"
;[758..771]:variation-type:"amplification"
;[808..833]:variation-type:"double-minute chromosomes"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[697..700] The) (NN:[701..705] cell) (NN:[707..711] line))
        (VP (VBN:[712..719] derived)
          (NP (-NONE-:[719..719] *))
          (PP-TMP (IN:[720..722] at)
            (NP (NN:[723..732] diagnosis)))))
      (PRN (-LRB-:[733..734] -LRB-)
        (NP (NN:[734..741] PER-106))
        (-RRB-:[741..742] -RRB-)))
    (VP (VBD:[743..752] exhibited)
      (NP (NN:[753..757] MYCN) (NN:[758..771] amplification))
      (PP (IN:[772..774] in)
        (NP
          (NP (DT:[775..778] the) (NN:[779..783] form))
          (PP (IN:[784..786] of)
            (NP
              (NP (JJ:[788..796] variable) (NNS:[797..804] numbers))
              (PP (IN:[805..807] of)
                (NP
                  (NP
                    (ADJP (JJ:[808..814] double) (HYPH:[814..815] -)
                          (JJ:[815..821] minute))
                    (NNS:[822..833] chromosomes))
                  (,:[833..834] ,)
                  (NP (JJ:[835..840] small) (NNS:[841..850] fragments))
                  (,:[850..851] ,) (CC:[852..855] and)
                  (NP
                    (NP (NNS:[856..861] rings))
                    (PP (IN:[862..864] of)
                      (NP (VBG:[866..873] varying) (NNS:[874..879] sizes)))))))))))
    (.:[879..880] .)))

;sentence 7 Span:881..1057
;This observed variability of MYCN amplification may explain the  reported
;heterogeneity of both MYCN mRNA and protein expression among individual 
;cells of some neuroblastomas.
;[910..914]:gene-rna:"MYCN"
;[915..928]:variation-type:"amplification"
;[977..981]:gene-protein:"MYCN"
;[977..981]:gene-rna:"MYCN"
;[1042..1056]:malignancy-type:"neuroblastomas"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[881..885] This) (VBN:[886..894] observed)
          (NN:[895..906] variability))
      (PP (IN:[907..909] of)
        (NP (NN:[910..914] MYCN) (NN:[915..928] amplification))))
    (VP (MD:[929..932] may)
      (VP (VB:[933..940] explain)
        (NP
          (NP (DT:[941..944] the) (VBN:[946..954] reported)
              (NN:[955..968] heterogeneity))
          (PP (IN:[969..971] of)
            (NP (CC:[972..976] both)
              (NP (NN:[977..981] MYCN) (NN:[982..986] mRNA))
              (CC:[987..990] and)
              (NP (NN:[991..998] protein) (NN:[999..1009] expression))))
          (PP (IN:[1010..1015] among)
            (NP
              (NP (JJ:[1016..1026] individual) (NNS:[1028..1033] cells))
              (PP (IN:[1034..1036] of)
                (NP (DT:[1037..1041] some) (NNS:[1042..1056] neuroblastomas))))))))
    (.:[1056..1057] .)))

;sentence 8 Span:1058..1217
;The cell lines derived from subsequent samples  (PER-107 and PER-108)
;contained amplified MYCN as two consistent homogeneously  staining regions in
;every cell.
;[1138..1147]:variation-type:"amplified"
;[1148..1152]:gene-rna:"MYCN"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1058..1061] The) (NN:[1062..1066] cell) (NNS:[1067..1072] lines))
      (VP (VBN:[1073..1080] derived)
        (NP (-NONE-:[1080..1080] *))
        (PP-CLR (IN:[1081..1085] from)
          (NP (JJ:[1086..1096] subsequent) (NNS:[1097..1104] samples)
            (PRN (-LRB-:[1106..1107] -LRB-)
              (NP (NN:[1107..1114] PER-107) (CC:[1115..1118] and)
                  (NN:[1119..1126] PER-108))
              (-RRB-:[1126..1127] -RRB-))))))
    (VP (VBD:[1128..1137] contained)
      (NP (VBN:[1138..1147] amplified) (NN:[1148..1152] MYCN))
      (PP (IN:[1153..1155] as)
        (NP (CD:[1156..1159] two) (JJ:[1160..1170] consistent)
          (ADJP (RB:[1171..1184] homogeneously) (VBG:[1186..1194] staining))
          (NNS:[1195..1202] regions)))
      (PP-LOC (IN:[1203..1205] in)
        (NP (DT:[1206..1211] every) (NN:[1212..1216] cell))))
    (.:[1216..1217] .)))

;sentence 9 Span:1218..1280
;These were located on the short arms of  chromosomes 6 and 14.
;[1244..1272]:variation-location:"short arms of  chromosomes 6"
;[1244..1270]...[1277..1279]:variation-location:"short arms of 
;chromosomes"..."14"
(SENT
  (S
    (NP-SBJ-1 (DT:[1218..1223] These))
    (VP (VBD:[1224..1228] were)
      (VP (VBN:[1229..1236] located)
        (NP-1 (-NONE-:[1236..1236] *))
        (PP-LOC (IN:[1237..1239] on)
          (NP
            (NP (DT:[1240..1243] the) (JJ:[1244..1249] short)
                (NNS:[1250..1254] arms))
            (PP (IN:[1255..1257] of)
              (NP
                (NP
                  (NML-2 (NNS:[1259..1270] chromosomes))
                  (CD:[1271..1272] 6))
                (CC:[1273..1276] and)
                (NP
                  (NML-2 (-NONE-:[1276..1276] *P*))
                  (CD:[1277..1279] 14))))))))
    (.:[1279..1280] .)))

;sentence 10 Span:1281..1427
;Thus, amplified MYCN was identified in each cell line and  demonstrated the
;concurrent evolution of amplification with cytogenetic  abnormalities.
;[1287..1296]:variation-type:"amplified"
;[1297..1301]:gene-rna:"MYCN"
;[1381..1394]:variation-type:"amplification"
(SENT
  (S
    (ADVP (RB:[1281..1285] Thus))
    (,:[1285..1286] ,)
    (NP-SBJ-1 (VBN:[1287..1296] amplified) (NN:[1297..1301] MYCN))
    (VP
      (VP (VBD:[1302..1305] was)
        (VP (VBN:[1306..1316] identified)
          (NP-1 (-NONE-:[1316..1316] *))
          (PP (IN:[1317..1319] in)
            (NP (DT:[1320..1324] each) (NN:[1325..1329] cell)
                (NN:[1330..1334] line)))))
      (CC:[1335..1338] and)
      (VP (VBD:[1340..1352] demonstrated)
        (NP
          (NP (DT:[1353..1356] the) (JJ:[1357..1367] concurrent)
              (NN:[1368..1377] evolution))
          (PP (IN:[1378..1380] of)
            (NP
              (NP (NN:[1381..1394] amplification))
              (PP (IN:[1395..1399] with)
                (NP (JJ:[1400..1411] cytogenetic)
                    (NNS:[1413..1426] abnormalities))))))))
    (.:[1426..1427] .)))

;section 11 Span:1431..1475
;PMID: 1581879 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1431..1435] PMID) (::[1435..1436] :) (CD:[1437..1444] 1581879)
        (NN:[1445..1446] -LSB-) (NNP:[1446..1452] PubMed) (::[1453..1454] -)
        (NN:[1455..1462] indexed) (IN:[1463..1466] for)
        (NNP:[1467..1475] MEDLINE-RSB-)))
